Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

EORTC/GIMEMA trial shows combination of GO and chemotherapy provides no benefit for older patients with AML

EORTC/GIMEMA trial shows combination of GO and chemotherapy provides no benefit for older patients with AML

REGARD VEGF receptor-2 as gastric cancer target

REGARD VEGF receptor-2 as gastric cancer target

Pancreatic cancer patients may benefit from antibody-drug conjugates

Pancreatic cancer patients may benefit from antibody-drug conjugates

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Research roundup: Less savings needed for retirement health expenses; falls as a predictor of surgical outcomes

Research roundup: Less savings needed for retirement health expenses; falls as a predictor of surgical outcomes

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Scientists to combine NK cell therapy with immunocytokine to target childhood cancer

Scientists to combine NK cell therapy with immunocytokine to target childhood cancer

Lakewood-Amedex, Wainwright enter into strategic advisory agreement

Lakewood-Amedex, Wainwright enter into strategic advisory agreement

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

Immunologic checkpoint inhibitor shows promise in malignant mesothelioma

Immunologic checkpoint inhibitor shows promise in malignant mesothelioma

Alefacept drug shows encouraging results in phase 2 trial for type 1 diabetes

Alefacept drug shows encouraging results in phase 2 trial for type 1 diabetes

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.